Product Description
An orally bioavailable, small molecule pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, pan-FGFR inhibitor ABSK-121 binds to and inhibits FGFR family proteins, including FGFR2 and FGFR3 gatekeeper, molecular brake, and activation loop mutations. This prevents FGFR-mediated signaling, and inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-fgfr-inhibitor-absk-121)
Mechanisms of Action: FGFR2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbisko
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05627063 |
ABSK121-NX-101 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2026-03-15 |
50% |
2025-09-11 |
|
CTR20231152 |
CTR20231152 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-09-14 |
Recent News Events
Date |
Type |
Title |
|---|